ADD A CATEGORY
MAY 20, 2013 - Benzinga
A Must Read - Share
In a report published Monday, Aegis Capital analyst Raghuram Selvaraju maintained the rating of Buy, and lowered the price target on Pernix Therapeutics (NASDAQ: PTX) to $8.50.
Hey you have no friends!!! Get to work and start inviting friends to help build your Comunitee. Click Here to invite friends.
© 2011 Comunitee, Inc.